Request Demo
Last update 17 Apr 2025
Travoprost/Timolol Maleate
Last update 17 Apr 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms DuoTrav APS, DuoTrav BAK, DuoTrav PQ + [11] |
Target |
Action agonists, antagonists |
Mechanism PTGFR agonists(Prostanoid FP receptor agonists), β-adrenoceptors antagonists(Beta adrenergic receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (23 Apr 2006), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC39H59F3N4O9S |
InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N |
CAS Registry874755-80-3 |
Related
36
Clinical Trials associated with Travoprost/Timolol MaleateNCT02730871
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)
NCT03966560
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma
NCT02003391
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
100 Clinical Results associated with Travoprost/Timolol Maleate
Login to view more data
100 Translational Medicine associated with Travoprost/Timolol Maleate
Login to view more data
100 Patents (Medical) associated with Travoprost/Timolol Maleate
Login to view more data
89
Literatures (Medical) associated with Travoprost/Timolol Maleate01 Aug 2024VACCINE
Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus
Article
Author: Luo, Ping ; Zhang, Yi ; Cheng, Xin ; Wu, Meilin ; Wang, Yi ; Li, Yuhang ; Gu, Jiang ; He, Qinggang ; Li, Xiaoyan ; Chen, Yuan ; Wan, Jiqing
The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.
05 Sep 2022Journal of epidemiologyQ3 · MEDICINE
Association of the Time to First Cigarette and the Prevalence of Chronic Respiratory Diseases in Chinese Elderly Population
Q3 · MEDICINE
ArticleOA
Author: Lou, Yiling ; Jiang, Heng ; Guo, Yingying ; Tian, Qingfeng ; Cao, Shiyi ; Gan, Yong ; Zhu, Yi ; Wang, Chao ; Lu, Zuxun
BACKGROUND:
Increasing number of studies have suggested the time to first cigarette after waking (TTFC) have significant positive effect on respiratory diseases. However, few of them focused on the Chinese population. This study aims to estimate the impact of TTFC on the prevalence of chronic respiratory diseases (CRD) in Chinese elderly and explore the association in different sub-populations.
METHODS:
Cross-sectional data of demographic characteristics, living environment, smoking-related variables, and CRD were drawn from the Chinese Longitudinal Healthy Longevity Survey in 2018. Multivariate stepwise logistic regression analyses were conducted to examine the association of the TTFC with the prevalence of CRD.
RESULTS:
This study includes 13,208 subjects aged 52 years and older, with a mean age of 85.3 years. Of them, 3,779 participants were ex- or current smokers (44.9% had the TTFC ≤30 minutes, 55.1% >30 minutes) and 1,492 had suffered from CRD. Compared with non-smokers, participants with TTFC ≤30 minutes seemed to have higher prevalence of CRD (OR 1.97; 95% CI, 1.65-2.35) than those with TTFC >30 minutes (OR 1.70; 95% CI, 1.44-2.00), although the difference was statistically insignificant (Pinteraction = 0.12). Compared with TTFC >30 minutes, TTFC ≤30 minutes could drive a higher prevalence of CRD among female participants, those aged 90 years and older, urban residents, and ex-smokers (Pinteraction < 0.05).
CONCLUSION:
Shorter TTFC relates to higher prevalences of CRD in Chinese older females, those aged 90 years and older, urban residents, and ex-smokers. Delaying TTFC might partially reduce its detrimental impact on respiratory disease in these specific subpopulations.
01 Dec 2020Microbial cell factoriesQ2 · ENGINEERING & TECHNOLOGY
A probiotic treatment increases the immune response induced by the nasal delivery of spore-adsorbed TTFC
Q2 · ENGINEERING & TECHNOLOGY
ArticleOA
Author: Baccigalupi, Loredana ; Isticato, Rachele ; Mazzoli, Arianna ; Iossa, Susanna ; Ricca, Ezio ; Santos, Francisco Denis S ; Maia, Ana Raquel ; Saggese, Anella ; Leite, Fabio
Abstract:
Background:
Spore-forming bacteria of the Bacillus genus are widely used probiotics known to exert their beneficial effects also through the stimulation of the host immune response. The oral delivery of B. toyonensis spores has been shown to improve the immune response to a parenterally administered viral antigen in mice, suggesting that probiotics may increase the efficiency of systemic vaccines. We used the C fragment of the tetanus toxin (TTFC) as a model antigen to evaluate whether a treatment with B. toyonensis spores affected the immune response to a mucosal antigen.
Results:
Purified TTFC was given to mice by the nasal route either as a free protein or adsorbed to B. subtilis spores, a mucosal vaccine delivery system proved effective with several antigens, including TTFC. Spore adsorption was extremely efficient and TTFC was shown to be exposed on the spore surface. Spore-adsorbed TTFC was more efficient than the free antigen in inducing an immune response and the probiotic treatment improved the response, increasing the production of TTFC-specific secretory immunoglobin A (sIgA) and causing a faster production of serum IgG. The analysis of the induced cytokines indicated that also the cellular immune response was increased by the probiotic treatment. A 16S RNA-based analysis of the gut microbial composition did not show dramatic differences due to the probiotic treatment. However, the abundance of members of the Ruminiclostridium 6 genus was found to correlate with the increased immune response of animals immunized with the spore-adsorbed antigen and treated with the probiotic.
Conclusion:
Our results indicate that B. toyonensis spores significantly contribute to the humoral and cellular responses elicited by a mucosal immunization with spore-adsorbed TTFC, pointing to the probiotic treatment as an alternative to the use of adjuvants for mucosal vaccinations.
100 Deals associated with Travoprost/Timolol Maleate
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Glaucoma | Japan | 16 Apr 2010 | |
| Glaucoma, Open-Angle | European Union | 23 Apr 2006 | |
| Glaucoma, Open-Angle | Iceland | 23 Apr 2006 | |
| Glaucoma, Open-Angle | Liechtenstein | 23 Apr 2006 | |
| Glaucoma, Open-Angle | Norway | 23 Apr 2006 | |
| Ocular Hypertension | European Union | 23 Apr 2006 | |
| Ocular Hypertension | Iceland | 23 Apr 2006 | |
| Ocular Hypertension | Liechtenstein | 23 Apr 2006 | |
| Ocular Hypertension | Norway | 23 Apr 2006 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 4 | 173 | hmwrxjhjzx(qxicppbohl) = yxscaufqtd cjkiirfyog (mgumhmtksu, 2.69) View more | - | 17 May 2019 | |||
(Vehicle + Duotrav) | hmwrxjhjzx(qxicppbohl) = ctkkruaawn cjkiirfyog (mgumhmtksu, 3.01) View more | ||||||
Phase 4 | 156 | Travoprost+Timolol | oejteafkzh(hzgckcbfss) = tywyizinjs xjeuxxftkb (kmcoftbbqd, 3.1) View more | Positive | 01 Jan 2017 | ||
beta-blocker monotherapy+Travoprost+Timolol | oejteafkzh(hzgckcbfss) = jsubampcxq xjeuxxftkb (kmcoftbbqd, 3.1) View more | ||||||
Phase 4 | 157 | exzljnjyzu(itaockmjvz) = scqjuljjhe zawktchugy (qnkhvvaqfn, apkqjjdotk - yqzsnltsqp) View more | - | 08 Aug 2016 | |||
Beta-blocker monotherapy+Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution (Beta-blocker) | exzljnjyzu(itaockmjvz) = xphdsgxdez zawktchugy (qnkhvvaqfn, yqlvmepjrk - rfcsvbiqix) View more | ||||||
Phase 4 | 135 | sposamazzl(ojfbpmqkmo) = lcpledrpgu lfvhvigrxb (zeouepozdd, 3.5) View more | - | 15 Aug 2014 | |||
sposamazzl(ojfbpmqkmo) = giycmmweej lfvhvigrxb (zeouepozdd, 2.7) View more | |||||||
Not Applicable | 50 | PQ-TTFC | dwvdqygtmu(wemknogrqf) = wjsisblxal uxryumwufp (abbkwyxapx ) View more | Positive | 01 Apr 2014 | ||
Phase 4 | 60 | ocauwzgyld(diavwgylvw) = sykeyuywfn rssukuiblo (wgnreowvnv, 1.0) View more | - | 10 Jan 2014 | |||
Phase 4 | 50 | rxhnaphuqp(viswdbmyop) = iapxawydty hvumjzsslm (iaqouopxsa, 3.6) View more | - | 08 Jul 2013 | |||
Phase 4 | 102 | Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination) | yqpdfgfjqf = mhrcjetrom anjswaticg (vjmealjzaz, ameirnbjfj - nqoxcyofoq) View more | - | 12 Jul 2012 | ||
(Travalert With Travoprost and Timolol) | yqpdfgfjqf = lonzgpvjlp anjswaticg (vjmealjzaz, ifgaqjpzxn - jcpiwqwaks) View more | ||||||
Phase 4 | - | Travoprost-Timolol Fixed-Combination | fycerydkqs(dhjwzagplk) = klvbrybegi ndabetknku (lgefwlmkln ) View more | - | 01 Apr 2010 | ||
Latanoprost-Timolol Fixed-Combination | fycerydkqs(dhjwzagplk) = ggujlwaufw ndabetknku (lgefwlmkln ) View more | ||||||
Not Applicable | 45 | (Normal subjects) | bjkfvmhvld(qvhftcaeud) = tzcflkmccv rbacjqjyst (wqruhpyyoj ) View more | - | 01 Apr 2010 | ||
Glaucoma patients treated with bimatoprost/timolol | bjkfvmhvld(qvhftcaeud) = mzchjqbgld rbacjqjyst (wqruhpyyoj ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free